Routine

Gynaecomastia (benign glandular breast enlargement in males)

gonadal · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Benign proliferation of male breast glandular tissue from a relative increase in oestrogen:androgen action. Physiological (neonatal, pubertal, elderly) or pathological: drugs (spironolactone, cimetidine, antiandrogens, antipsychotics, cannabis, anabolic steroids), hypogonadism, hyperthyroidism, liver/renal disease, refeeding, and (rarely) oestrogen/hCG-secreting tumours. Must be distinguished from pseudogynaecomastia (fat) and breast cancer.

Red flags

  • Hard, fixed, eccentric mass; nipple retraction/discharge/bleeding; skin change; axillary nodes — suspect male breast cancer
  • Testicular mass or raised beta-hCG — germ-cell/oestrogen-secreting tumour
  • Rapidly enlarging or markedly asymmetrical breast tissue
  • Associated weight loss / systemic features

Assessment

Differential diagnosis

  • Pseudogynaecomastia (adipose tissue, no firm subareolar disc)
  • Male breast cancer (hard, eccentric, fixed, nipple change, lymphadenopathy — unilateral)
  • Lipoma, dermoid, abscess/mastitis
  • Drug-induced (very common — review every medication)
  • Underlying hypogonadism, hyperthyroidism, chronic liver/renal disease
  • hCG- or oestrogen-secreting tumour (testicular, adrenal, lung)

Investigations

  • Clinical exam: concentric firm rubbery subareolar disc (gynaecomastia) vs eccentric hard mass (?cancer); examine testes
  • If pathological features/rapid onset: testosterone, LH, FSH, oestradiol, prolactin, hCG (beta-hCG), TSH/free T4
  • LFTs, U&E/eGFR (liver/renal cause), review drug history thoroughly
  • If beta-hCG raised or testicular mass: testicular ultrasound +/- imaging for germ-cell/other tumour
  • Mammography/ultrasound +/- biopsy if suspicious for malignancy
  • Consider karyotype if hypogonadism with small firm testes (Klinefelter — increased breast cancer risk)

Management

  • Confirm true gynaecomastia vs pseudogynaecomastia vs cancer on examination
  • Review and stop/switch causative drugs where possible, then reassess
  • Identify and treat underlying cause (hypogonadism, thyrotoxicosis, liver/renal disease, tumour)
  • Reassure for physiological/pubertal cases — most resolve within 1-2 years; observe
  • Painful recent (<12 months, proliferative) gynaecomastia may respond to a trial of tamoxifen
  • Longstanding fibrotic gynaecomastia and cosmetic concern → surgical referral (it will not regress medically)
  • Urgent breast referral for any features suggesting malignancy

Drugs & doses

No drug for physiological/pubertal gynaecomastia — reassure and observe
Tamoxifen 10-20 mg PO od for 3-6 months — for painful, recent, proliferative gynaecomastia [off-label, verify local]
Treat the cause: testosterone replacement if hypogonadal (see hypogonadism entry); antithyroid therapy if thyrotoxic
Stop/substitute culprit drug (e.g. switch spironolactone to eplerenone) where clinically possible

Disposition

Outpatient. Reassure/observe physiological cases. Urgent breast clinic for suspicious features; endocrine workup and surgical referral as indicated. Not an acute ED condition.

Complications & pitfalls

  • Psychological distress
  • Missed male breast cancer or testicular tumour if not examined
  • Fibrosis making longstanding gynaecomastia irreversible to medical therapy

Exam pearls

  • Always examine the testes and review the full drug list — drugs and hypogonadism are the common reversible causes.
  • A firm concentric subareolar disc is benign gynaecomastia; a hard eccentric fixed mass needs urgent cancer workup.
  • Pubertal gynaecomastia usually resolves spontaneously within 1-2 years — reassure and avoid over-investigation.
  • Medical therapy (tamoxifen) only helps early proliferative/painful disease; fibrotic longstanding tissue needs surgery.
  • Check beta-hCG and oestradiol if rapid onset in an adult to exclude a hormone-secreting tumour.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.